Program
tenofovir alafenamide
Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.
Drug pageTenofovir alafenamide: every studyMany companies study it; this page follows only the 61 they lead. All 140 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 499 open or running | phase 4since Oct 23, 2023 | May 13, 2002 | Jun 2027phase 4 · NCT06337032 |
| Johnson & Johnsonits history only | 70 open or running | phase 3since Oct 17, 2014 | Oct 17, 2014 | none ahead |
| Henan Genuine Biotechits history only | 10 open or running | phase 1since May 13, 2025 | May 13, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 9, 2024 | Sep 9, 2024 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Dec 6, 2019 | Dec 6, 2019 | none ahead |
| The Crofoot Research Centerits history only | 10 open or running | phase 4since May 12, 2020 | May 12, 2020 | none ahead |
| Xiamen Amoytop Biotechits history only | 11 open or running | no phasesince Nov 24, 2024 | Nov 24, 2024 | May 31, 2029NCT06707922 |
Also a collaborator on its studies: Merck and F-star Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since May 13, 2002.
- Jan 12, 2018Phase 3 study in HIV-1 InfectionNCT03405935 · 86 enrolled · Belgium, France, Italy and more
- Feb 9, 2018Phase 2 study in Hepatitis B, ChronicNCT03434353 · 123 enrolled · Hong Kong, Korea, Republic of
- May 24, 2018Phase 3 study in HIV-1/HBV Co-InfectionNCT03547908 · 244 enrolled · United States, China, Dominican Republic and more
- Aug 13, 2018Phase 3 study in HIV-1 InfectionNCT03631732 · 496 enrolled · United States
- Nov 2, 2018Phase 1 study in HIV-1 InfectionNCT03739866 · 53 enrolled · United States
- May 21, 2019Phase 1 study in HIV-1-infectionNCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
- Oct 28, 2019Phase 2 study in HIV-1-infectionNCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
- Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionNCT04994509 · 5,368 enrolled · South Africa, Uganda
- Oct 23, 2023Phase 4 study in HIV-1-infectionNCT06104306 · 33 enrolled · United States, Canada, France
- Mar 22, 2024Phase 4 study in HIV-1-infectionNCT06337032 · 350 planned · Argentina, Panama, South Africa and more
- Oct 4, 2024Phase 3 study in HIV-1-infectionNCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Jun 27, 2025Phase 1 study in HIV-1-infectionNCT07055451 · 16 enrolled · United States, South Africa
- Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionNCT07708727 · 700 planned · United States, Canada, Germany and more
Ahead
- Jun 2027Primary completion: phase 4 study in HIV-1-infectionNCT06337032
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionNCT07055451
- Oct 2030Primary completion: phase 3 study in HIV-1-infectionNCT07708727
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 49 Gilead Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Aug 2027 | 175 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Mar 2028 | 16 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 17, 2026 | 609 |
| NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more | 4 | Recruiting | Jun 2027 | 350 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Jan 29, 2025 | 33 |
| NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda | 3 | Active, not recruiting | May 27, 2024 | 5,368 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Jul 21, 2022 | 62 |
| NCT03739866HIV-1 Infection · United States | 1 | Completed | Nov 14, 2019 | 53 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Feb 25, 2022 | 244 |
| NCT03434353Hepatitis B, Chronic · Hong Kong, Korea, Republic of | 2 | Terminated | Jan 20, 2020 | 123 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Nov 20, 2018 | 86 |
| NCT03180619Hepatitis B, Chronic · United States, Canada, Hong Kong and more | 2 | Completed | Mar 27, 2019 | 124 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Dec 4, 2018 | 567 |
| NCT02932150Hepatitis B, Chronic · United States, Belgium, Hong Kong and more | 2 | Active, not recruiting | Oct 27, 2026 | 150 |
| NCT02881320HIV-1 Infection · United States, South Africa, Thailand and more | 3 | Active, not recruiting | Mar 24, 2025 | 177 |
| NCT02862548Hepatitis B, Chronic · New Zealand | 2 | Completed | Feb 8, 2018 | 51 |
| NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more | 3 | Terminated | Jan 31, 2019 | 5,399 |
| NCT02836249Hepatitis · China | 3 | Completed | Mar 21, 2017 | 181 |
| NCT02836236Hepatitis · China | 3 | Completed | Apr 5, 2017 | 155 |
| NCT02707601Hepatitis C · United States, Puerto Rico | 3 | Completed | Sep 14, 2017 | 150 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Oct 9, 2017 | 472 |
| NCT02616029HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Oct 11, 2018 | 66 |
| NCT02616783HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Feb 21, 2018 | 167 |
| NCT02605954HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Jun 14, 2017 | 275 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | May 12, 2017 | 657 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Sep 29, 2017 | 55 |
| NCT02469246HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Dec 11, 2017 | 567 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Nov 30, 2015 | 98 |
| NCT02296853Hepatitis B · United States, Germany, New Zealand | 1 | Completed | Apr 17, 2015 | 20 |
| NCT02276612HIV · United States, South Africa | 3 | Completed | Nov 10, 2016 | 60 |
| NCT02121795HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Aug 12, 2015 | 668 |
| NCT02071082Coinfection · United States, Canada, Japan | 3 | Completed | Jan 23, 2015 | 79 |
| NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more | 3 | Active, not recruiting | Jun 13, 2025 | 133 |
| NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more | 3 | Completed | May 21, 2015 | 55 |
| NCT01968551HIV Infections · United States, Canada | 3 | Completed | Jul 21, 2015 | 158 |
| NCT01940471Hepatitis · United States, Australia, Bulgaria and more | 3 | Completed | Nov 16, 2015 | 875 |
| NCT01940341Hepatitis · United States, Australia, Canada and more | 3 | Completed | Sep 30, 2015 | 426 |
| NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more | 3 | Completed | May 11, 2020 | 129 |
| NCT01818596HIV Infections · United States, Australia, Dominican Republic and more | 3 | Completed | Jul 31, 2014 | 252 |
| NCT01815736HIV Infections · United States, Australia, Austria and more | 3 | Completed | Mar 16, 2015 | 1,443 |
| NCT01797445HIV Infections · United States, Canada, Dominican Republic and more | 3 | Completed | Sep 19, 2014 | 872 |
| NCT01780506HIV Infections · United States, Australia, Austria and more | 3 | Completed | Aug 26, 2014 | 872 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Apr 2013 | 51 |
| NCT01565850Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Jan 2013 | 153 |
| NCT01497899Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Oct 17, 2012 | 279 |
| NCT00036634HIV Infections · United States | 2 | Completed | Feb 2003 | 30 |
How it is read
Names in the registry
- “E/C/F/TAF”, 17 entries
- “TAF”, 12 entries
- “B/F/TAF”, 10 entries
- “F/TAF”, 8 entries
- “B/F/TAF (TOS)”, 4 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 11 studies
- Hepatitis B, Chronic, 10 studies
- HIV Infections, 7 studies
- Hepatitis, 4 studies
- Coinfection, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.